30-1 Nihonbashi Hakozakicho
3rd Floor A.i.Nihombashi EAST Chuo-ku
Tokyo 103-0015
Japan
81 3 6264 8268
https://www.ppmx.com
Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 24
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Takuya Yokokawa | President, CEO, Executive Officer & Chairman | N/A | N/A | 1960 |
Tadashi Matsuura | CTO & Executive Officer | N/A | N/A | 1959 |
Mr. Shinichi Suzukawa | Head of Administrative Dept, Executive Officer & Director | N/A | N/A | 1955 |
Mr. Shinji Hagiwara | Executive Officer, Head of R&D Dept., Head of Business Development Dept. and Director | N/A | N/A | 1965 |
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Perseus Proteomics Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.